Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Liabilities (2016 - 2026)

Aytu Biopharma has reported Total Liabilities over the past 15 years, most recently at $107.8 million for Q4 2025.

  • Quarterly Total Liabilities rose 26.14% to $107.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.8 million through Dec 2025, up 26.14% year-over-year, with the annual reading at $105.2 million for FY2025, 16.41% up from the prior year.
  • Total Liabilities was $107.8 million for Q4 2025 at Aytu Biopharma, up from $101.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $128.1 million in Q2 2021 and troughed at $85.5 million in Q4 2024.
  • The 5-year median for Total Liabilities is $100.7 million (2023), against an average of $101.4 million.
  • Year-over-year, Total Liabilities surged 131.5% in 2021 and then dropped 27.15% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $118.3 million in 2021, then fell by 19.16% to $95.6 million in 2022, then increased by 2.9% to $98.4 million in 2023, then fell by 13.14% to $85.5 million in 2024, then increased by 26.14% to $107.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Total Liabilities are $107.8 million (Q4 2025), $101.8 million (Q3 2025), and $105.2 million (Q2 2025).